After the GLP-1 wave: what formulators now have to deliver 

Quick answer

GLP-1 receptor agonists (semaglutide, tirzepatide) reduce food intake and accelerate weight loss, creating a set of physiological deficits that formulators across nutraceuticals, food & beverage and cosmetics now have to address. The key ingredient categories are: protein and amino acids for lean mass preservation; creatine monohydrate to support resistance exercise capacity and healthy ageing; prebiotic fibres and digestive actives for gastrointestinal tolerance; vitamins and minerals to close nutrient gaps from reduced intake; botanical extracts with clinically studied effects on fat mass and metabolic health, such as Moro orange extract (Morosil); and topical actives targeting skin laxity and volume loss ("Ozempic face"), including hyaluronic acid, collagen-stimulating peptides and antioxidants. Delivery format matters as much as ingredient selection: GLP-1 users feel full quickly, so products need to be low-volume, easy to tolerate, and nutrient-dense.

GLP-1 receptor agonists — the drug class behind Ozempic, Wegovy and Mounjaro — have moved from a pharmaceutical story to a consumer-behaviour story. According to clinical research published in the New England Journal of Medicine, once-weekly semaglutide produces sustained, significant reductions in food intake and body weight; in practice that means people are eating less, eating differently, and experiencing measurable physical changes — muscle loss, nutrient gaps and skin laxity among them.  

As Nutrition Insight reported, US nutrition and health experts ranked the expansion of GLP-1 medication as the single greatest influence on the sector for 2026. For a specialty ingredient distributor, this is not a marketing trend to observe from a distance. It is a change in the brief itself: the consumer the formulator designs for now eats smaller portions, tolerates less, and carries new physiological deficits — and the food, supplement or skincare product has to account for all three. 

What does that mean in the formulation lab? Smaller products that must deliver more protein, more fibre and more functional actives per gram; gentler systems for skin and digestion under stress; and delivery formats built for someone who feels full fast. The commercial scale behind that brief is now substantial. One assessment values the GLP-1 nutrition and muscle-health market at USD 3.8 billion in 2025, rising to nearly USD 19 billion by 2032, and is explicit that GLP-1-driven reformulation — resistant starches, prebiotic fibres, pulse proteins, sweetener systems and texture solutions — is becoming the foundation of the category rather than a niche.  

A separate GLP-1 supplement market forecast projects steady double-digit annual growth through 2034, driven specifically by demand for muscle preservation, hydration and digestive wellness. The signal across every forecast is the same: the consumer changed, and the ingredient strategy — from protein and collagen to hyaluronic acid and prebiotic fibre — has to change with them. 

Nutraceuticals: the sharpest, most immediate shift 

This is where the GLP-1 effect is most direct. Reduced appetite means lower food intake, which creates nutrient gaps; rapid weight management drives muscle loss; and slowed gastric emptying produces nausea and constipation. The January 2026 nutrition review named the expansion of GLP-1 medication as the single greatest influence on nutrition innovation for the year, with protein and fibre as the defining nutrients. 

The formulator's brief, broken down: 

• Protein and amino acids to counter muscle loss — the dominant product segment, with condition-specific blends for lean-mass preservation. 

• Vitamins and minerals to close the deficiency gap created by eating less (iron, magnesium, vitamin D among the most cited). 

• Electrolytes and hydration support to address reduced fluid and sodium/potassium intake. 

• Digestive and prebiotic-fibre support for the GI side effects of slowed gastric emptying. 

• Delivery formats that work for a consumer who feels full fast: low-volume, easy-to-tolerate, ready-to-drink and powder formats over bulky doses. 

This is where the GLP-1 effect is most direct. Reduced appetite means lower food intake, which creates nutrient gaps; rapid weight management drives muscle loss; and slowed gastric emptying produces nausea and constipation. The January 2026 nutrition review named the expansion of GLP-1 medication as the single greatest influence on nutrition innovation for the year, with protein and fibre as the defining nutrients. 

The formulator's brief, broken down: 

• Protein and amino acids to counter muscle loss — the dominant product segment, with condition-specific blends for lean-mass preservation. 

• Vitamins and minerals to close the deficiency gap created by eating less (iron, magnesium, vitamin D among the most cited). 

• Electrolytes and hydration support to address reduced fluid and sodium/potassium intake. 

• Digestive and prebiotic-fibre support for the GI side effects of slowed gastric emptying. 

• Delivery formats that work for a consumer who feels full fast: low-volume, easy-to-tolerate, ready-to-drink and powder formats over bulky doses. 

Food & beverage: more nutrition in a smaller package 

If nutraceuticals answer the deficiency, food and beverage has to answer the portion. GLP-1 users eat smaller amounts and gravitate away from high-fat, high-sugar and high-volume products. The challenge handed to the formulator is density: deliver more protein, more fibre and more satiety in a product that is physically smaller, without it feeling heavy or hard to finish. 

The GLP-1 reformulation analysis is specific about the toolkit: resistant starches, prebiotic fibres, pulse proteins, sweetener systems and texture solutions that raise nutrient density while cutting sugar and portion size. The formulator's brief here is: 

• Protein fortification — plant and dairy systems engineered for high inclusion without grit or off-notes. 

• Sugar reduction — sweetener systems that hold taste at lower sugar loads. 

• Satiety and fibre — resistant starches and prebiotic fibres that extend fullness in a smaller serving. 

• Texture and mouthfeel — so concentrated, smaller-format products still feel pleasant to eat. 

• Flavour masking — essential once protein and fibre loads rise. 

The protein conversation itself has already moved on, as our plant protein trends piece describes: the old brief — grams per serving, PDCAAS score, pea-versus-soy — has given way to a more sophisticated set of expectations around functionality, texture and tolerance. GLP-1 reformulation accelerates exactly that shift, because the product has less room to hide a poor-performing protein. 

Cosmetics: a new category built on rapid weight management 

The cosmetics link is less obvious but increasingly well documented. Rapid GLP-1 weight management causes facial volume loss, sagging and reduced elasticity — the so-called “Ozempic face.” As CosmeticsDesign-Europe reported from the IMCAS cosmetic-dermatology conference, brands in the aesthetic space were vocal early about how these drugs are changing facial structure. The mechanism is not only fat loss: published endocrinology research describes how GLP-1 receptor activity reduces collagen production via effects on adipose-derived stem cells, oxidative stress and reduced fibroblast stimulation. 

The commercial consequence is that an entirely new skincare category is emerging, designed specifically for the aesthetic side effects of GLP-1 use. Early launches are built on amino acids to stimulate collagen, hyaluronic acid for plumping, biomimetic plant-collagen fragments for firmness, and encapsulated antioxidants such as vitamin C and astaxanthin to fight oxidative stress and reinforce the barrier. The formulator's brief is to rebuild structural support on skin that is already under stress, gently. 

That maps cleanly onto actives Safic-Alcan already distributes: 

• BIO HA-MIX (Hyundai Bioland) — a multi-weight hyaluronic acid system for anti-aging and moisturisation, targeting exactly the volume and hydration loss of “Ozempic face.” 

• Amino Acid Complex (B) (Hyundai Bioland) — a water-soluble amino-acid active that proliferates skin fibroblasts and provides nutrients to skin cells. 

• Skin Save™ (Bionap) — a natural active from a supplier whose portfolio spans both skin care and the nutraceutical concerns (cardiovascular, gastrointestinal, immune) that accompany GLP-1 use — useful for an inside-and-out positioning. 

CORUM's anti-aging peptide range, which Safic-Alcan distributes (see EPI-ON™), adds the collagen-stimulation and fibroblast-signalling angle that sits at the centre of the post-GLP-1 skincare brief. 

The connecting idea: inside and out 

The strongest position for a specialty distributor is not to treat these as three separate trends but as one consumer story told across three categories. The same person preserving muscle with a collagen or protein supplement is also addressing skin laxity with a topical collagen-stimulating active, and reaching for smaller, denser, gentler food. Collagen is the clearest bridge — ingested for muscle, joints and beauty-from-within, applied topically for firmness — and it is a category Safic-Alcan already owns content and portfolio in. 

For formulators and brand teams, the practical takeaway is that the GLP-1 wave rewards technical partners who can help a smaller product, or a stressed skin, do more. That is precisely the brief Safic-Alcan's market specialists and application labs are built to support — from ingredient selection through to finished formulation concepts. 

Frequently asked questions 

What ingredients help with GLP-1 (Ozempic) muscle loss? 

Muscle loss is one of the most documented effects of rapid GLP-1 weight management, which is why protein and amino acids are the dominant segment of GLP-1 companion nutrition. Formulators are using protein systems, condition-specific amino-acid blends and collagen peptides to support lean-mass preservation, typically in low-volume, easy-to-tolerate formats such as ready-to-drink shakes and powders for consumers who feel full quickly. 

How should food and beverage brands reformulate for GLP-1 consumers? 

The core challenge is nutrient density: delivering more protein, fibre and satiety in a physically smaller product. Reformulation typically draws on resistant starches, prebiotic fibres, pulse proteins, sweetener systems and texture solutions to raise nutrient density while reducing sugar and portion size, supported by flavour masking once protein and fibre loads increase. 

What causes “Ozempic face” and which skincare ingredients address it? 

“Ozempic face” refers to facial volume loss, sagging and reduced elasticity following rapid GLP-1 weight management. The mechanism combines loss of subcutaneous fat with reduced collagen and elastin. Topical formulations target it with collagen-stimulating actives, amino acids, hyaluronic acid for volume and hydration, and encapsulated antioxidants to counter oxidative stress and reinforce the skin barrier — formulated gently for skin already under stress. 

What specialty ingredients support GLP-1 companion nutrition? 

Across the GLP-1 journey, formulators draw on protein and amino acids for muscle preservation, vitamins and minerals to close intake-driven nutrient gaps, electrolytes for hydration, prebiotic fibre and digestive support for gastrointestinal tolerance, and collagen as a bridge between muscle, joint and beauty-from-within positioning. Safic-Alcan supports formulators across these categories in cosmetics, nutraceuticals and food & beverage./